| [1] |
ZHONG Wei, SHI Shuxia, QIN Qinyue, YU Guo.
Measurement tools and rationality evaluation of clinical research coordinator's work ability and workload
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 937-947.
|
| [2] |
DAI Jiahui, SUN Sijia, XIE Xuefeng.
Quality management and indicator system for clinical trials of medical devices
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 51-58.
|
| [3] |
SHI Gexin, CHONG Rui, HE Kun, WU Haitang, ZHOU Yu, DUN Zhongjun, WEN Qing, ZHANG Jiguo, ZHANG Rong.
A fully replicated crossover bioequivalence study of mycophenolate mofetil capsules in Chinese healthy male subjects under fasting and fed conditions
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1255-1263.
|
| [4] |
HE Jie, LIU Dongxue, ZHONG Lingjun, SHAO Hua, HU Linlin.
Establishment of a limited sampling strategy to estimate micafungin exposure in critically ill patients
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1264-1271.
|
| [5] |
XU Liying, ZHANG Gaosong, HUANG Xiaomin, HUANG Jihan, WANG Shuhua.
Clinical efficacy and modeling evaluation of He-wei-zhi-xie capsules in treating diarrhea patients
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 47-55.
|
| [6] |
CHE Jinjing, LI Na.
General considerations on bioanalytical methods for comparative evaluation of biosimilars immunogenicity
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 721-728.
|
| [7] |
SUN Yuchen, LIU Yinhui, ZHANG Xian, YUAN Tong, JING Mengyao, ZAHNG Xinyu, YANG Jin.
Exploration of screening criteria for healthy volunteers in human bioequivalence clinical trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 714-720.
|
| [8] |
BAI Liuanning, XIA Jielai, WANG Ling, YUAN Yukun, LI Chen.
Common bias and its control in real-world study
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(12): 1422-1428.
|
| [9] |
GUO Wei, XIE Linli, CAO Liya, XIE Jiangchuan, XIA Peiyuan, CHEN Yongchuan.
Analysis of the current status of clinical drug trial institutions in Chongqing and reflections on the establishment of regional institutions
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(10): 1125-1130.
|
| [10] |
XIE Mengsheng, ZHAO Yang, CHEN Feng.
Statistical analysis of active extension trial
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1007-1013.
|
| [11] |
ZHANG Yanping, PEI Tong, HU Chaoying, ZHANG Lan.
Brief analysis on the measures for the management of instruments and equipment in phase Ⅰ drug clinical trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 890-894.
|
| [12] |
LI Jian, YAN Fang, YANG Jinbo, WANG Yuzhu.
Application of model-informed drug development approach in dose optimization: Insights from the modification of nivolumab dosage regimen
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 408-412.
|
| [13] |
YANG Haijing, YU Jicheng, WANG Jingjing, LI Nanyang, WU Jufang, ZHANG Hai, XUE Tao, DAI Weiguo, DING Tianling, CAO Guoying.
Risk management of biological agents in phase I clinical trials: Case sharing
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 44-48.
|
| [14] |
LIU Yaqi, LU Mengjie, LIU Yuxiu, CHEN Yu, YUAN Yangdan, ZHOU Chongchong, LIU Man.
Blinded analysis of double-blind randomized controlled trial for unequal integer ratio grouping
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1155-1160.
|
| [15] |
DAI Lei, LUO Linghe, WU Liyan, WANG Gang, FEI Baoying.
Expression of miR-222 and MBD2 in gastric cancer patients and their effects on platinum chemosensitivity
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 623-629.
|
